Author: NSV

Isorg raises €16 million in Series C financing

Isorg raises €16 million in Series C financing

Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund

Read More
Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients

Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients

Read More
Phase Four raises $26m led by New Science Ventures

Phase Four raises $26m led by New Science Ventures

Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create

Read More
Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range of applications including AI/ML, 5G infrastructure, networking,

Read More
ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors and new investments by Fidelity Management & Research

Read More
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs. Ventyx Biosciences combines assets from three formerly

Read More
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking place March 3-10, 2021. During the congress, the Company also showcased the full suite

Read More
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition Profile (FAP) 10 module has received FBI certification, the first in this category of organic photodiode (OPD) based optical sensors. The FAP 10 biometrics module is now approved for use in security applications, in

Read More
iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included

Read More
DataCore Software acquires Caringo, Inc.

DataCore Software acquires Caringo, Inc.

DataCore Software, the authority on software-defined storage, today announced that it has acquired Caringo, Inc. The combined entity will enable DataCore to offer complete, best-of-breed software-defined storage solutions for block, file, and object—from a single vendor. The acquisition will also add talent and expertise to the DataCore team, as well

Read More
New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence

New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence

New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, today announces the merger of its portfolio company, Achronix Semiconductor Corporation (“Achronix”), with ACE Convergence Acquisition Corp. NSV is a founding investor in Achronix. Highlights: Achronix is the

Read More
NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative therapies for NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory, and fibrotic diseases based on its SEFA (Structurally Engineered Fatty Acid) technology, today announced a positive interim readout of its ICONA Phase 2b study. The ICONA study (ICOsabutate in

Read More